4.3. Treatment of HBV-Carrying CBA/CaJ Mice
Mice were divided into eight groups to investigate the effect of rmIFN-α on sequential combination with anti-mouse PD1. The drug dosages and administration routes are described below.Group 1 (control): Six HBV-carrying CBA/CaJ mice were subcutaneously (s.c.) injected with 200 μL of PBS every other day (Q2D) × 8 (days 0–14).Group 2: Six HBV-carrying CBA/CaJ mice were s.c. injected with 800 IU/g of rmIFN-α (Q2D × 8, days 0–14).Group 3: Six HBV-carrying CBA/CaJ mice were s.c. injected with 800 IU/g of rmIFN-α (Q2D × 22, days 0–42)Group 4: Ten HBV-carrying CBA/CaJ mice were intraperitoneally (i.p.) injected with 32 μg/g of the anti-mouse PD1 antibody (Q2D × 6, days 16–26).Group 5: Ten HBV-carrying CBA/CaJ mice were i.p. injected with 32 μg/g of anti-mouse PD1 antibody (Q2D × 10, days 16–34).Group 6: Ten HBV-carrying CBA/CaJ mice were s.c. injected with 800 IU/g of rmIFN-α (Q2D × 8, days 0–14) and then i.p. injected with 32 μg/g of the anti-PD1 antibody (Q2D × 6, days 16–26).Group 7: Ten HBV-carrying CBA/CaJ mice were s.c. injected with 800 IU/g of rmIFN-α (Q2D × 22, days 0–42) and then i.p. injected with 32 μg/g of the anti-PD1 antibody (Q2D × 6, days 44–54).Group 8: Ten HBV-carrying CBA/CaJ mice were s.c. injected with 800 IU/g of rmIFN-α (Q2D × 43, days 0–84) and then i.p. injected with 32 μg/g of the anti-PD1 antibody (Q2D × 6, days 86–96).